MORPHIC HOLDING INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei MORPHIC HOLDING INC listata cu simbolul US.MORF ==Descriere companie== Morphic Holding, Inc. (https://morphictx.com/) is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibr...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei MORPHIC HOLDING INC listata cu simbolul US.MORF | Pagina dedicata companiei MORPHIC [[HOLDING]] INC listata cu simbolul US.MORF | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 2 octombrie 2024 05:44
Pagina dedicata companiei MORPHIC HOLDING INC listata cu simbolul US.MORF
Descriere companie[edit | ]
Morphic Holding, Inc. (https://morphictx.com/) is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an Alpha 4 and Beta 7-specific integrin inhibitor affecting inflammation, for the treatment of inflammatory bowel disease (IBD). It has also developed oral αvb6-specific integrin inhibitors including MORF-720 and MORF-627, for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Company is using its MInT Platform to advance a pipeline of preclinical programs across a variety of therapeutic areas.
Grafic actiuni companie[edit | ]